Cargando…
Refractory relapsing polychondritis: challenges and solutions
Relapsing polychondritis is a severe systemic immune-mediated disease characterized by an episodic and progressive inflammatory condition with progressive destruction of cartilaginous structures. This disease has for nearly a century kept secrets not yet explained. The real incidence and prevalence...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768290/ https://www.ncbi.nlm.nih.gov/pubmed/29391837 http://dx.doi.org/10.2147/OARRR.S142892 |
_version_ | 1783292679964065792 |
---|---|
author | Lekpa, Fernando Kemta Chevalier, Xavier |
author_facet | Lekpa, Fernando Kemta Chevalier, Xavier |
author_sort | Lekpa, Fernando Kemta |
collection | PubMed |
description | Relapsing polychondritis is a severe systemic immune-mediated disease characterized by an episodic and progressive inflammatory condition with progressive destruction of cartilaginous structures. This disease has for nearly a century kept secrets not yet explained. The real incidence and prevalence of this rare disease are unknown. The multiple clinical presentations and episodic nature of relapsing polychondritis cause a significant diagnosis delay. No guidelines for the management of patients with relapsing polychondritis have been validated to date. The challenges remain, both in the understanding of its pathophysiology and diagnosis, evaluation of its activity and prognosis, and its treatment. Possible solutions involve the sharing of data for relapsing polychondritis from worldwide reference centers. Thus, we would be able to evolve toward a better knowledge of its pathophysiology, the publication of new diagnosis criteria, which will include biological markers and imaging findings, the prediction of life-threatening or organ-threatening situations, and the publication of therapeutic evidence-based guidelines after performing at randomized controlled trials. |
format | Online Article Text |
id | pubmed-5768290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-57682902018-02-01 Refractory relapsing polychondritis: challenges and solutions Lekpa, Fernando Kemta Chevalier, Xavier Open Access Rheumatol Review Relapsing polychondritis is a severe systemic immune-mediated disease characterized by an episodic and progressive inflammatory condition with progressive destruction of cartilaginous structures. This disease has for nearly a century kept secrets not yet explained. The real incidence and prevalence of this rare disease are unknown. The multiple clinical presentations and episodic nature of relapsing polychondritis cause a significant diagnosis delay. No guidelines for the management of patients with relapsing polychondritis have been validated to date. The challenges remain, both in the understanding of its pathophysiology and diagnosis, evaluation of its activity and prognosis, and its treatment. Possible solutions involve the sharing of data for relapsing polychondritis from worldwide reference centers. Thus, we would be able to evolve toward a better knowledge of its pathophysiology, the publication of new diagnosis criteria, which will include biological markers and imaging findings, the prediction of life-threatening or organ-threatening situations, and the publication of therapeutic evidence-based guidelines after performing at randomized controlled trials. Dove Medical Press 2018-01-09 /pmc/articles/PMC5768290/ /pubmed/29391837 http://dx.doi.org/10.2147/OARRR.S142892 Text en © 2018 Kemta Lekpa and Chevalier. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed |
spellingShingle | Review Lekpa, Fernando Kemta Chevalier, Xavier Refractory relapsing polychondritis: challenges and solutions |
title | Refractory relapsing polychondritis: challenges and solutions |
title_full | Refractory relapsing polychondritis: challenges and solutions |
title_fullStr | Refractory relapsing polychondritis: challenges and solutions |
title_full_unstemmed | Refractory relapsing polychondritis: challenges and solutions |
title_short | Refractory relapsing polychondritis: challenges and solutions |
title_sort | refractory relapsing polychondritis: challenges and solutions |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768290/ https://www.ncbi.nlm.nih.gov/pubmed/29391837 http://dx.doi.org/10.2147/OARRR.S142892 |
work_keys_str_mv | AT lekpafernandokemta refractoryrelapsingpolychondritischallengesandsolutions AT chevalierxavier refractoryrelapsingpolychondritischallengesandsolutions |